echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > FDA today approves innovative hepatitis B adult vaccine targeting multiple viral antigens for the first time

    FDA today approves innovative hepatitis B adult vaccine targeting multiple viral antigens for the first time

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 1, 2021, VBI Vaccines announced that the US FDA has approved the third-generation hepatitis B virus (HBV) vaccine PreHevbrio (Sci-B-Vac) to be used to prevent all known HBV in adults 18 years and older Infections caused by subtypes


    Hepatitis B is one of the most important infectious disease threats in the world, with more than 290 million people infected worldwide


    PreHevbrio is the third-generation hepatitis B vaccine developed by VBI Vaccines.


    Image source: VBI Vaccines official website

    The approval of PreHevbrio is based on the positive results of two pivotal Phase 3 clinical trials


    The comprehensive safety analysis of the two trials showed that the vaccine is well tolerated and has no unanticipated reactogenicity


    Reference materials:

    [1] VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.